Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin–angiotensin system activity in obese hypertensive patients

Abstract

In obese hypertensive patients, aliskiren penetrates adipose and skeletal muscle tissue at levels that are apparently sufficient to reduce tissue RAS activity. Furthermore, tissue binding may contribute to aliskiren's prolonged blood pressure-lowering effect following discontinuation.